Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 induction study of RO7790121 versus placebo in moderately to severely active ulcerative colitis
MOH_2024-11-26_013759Phase 3Active, not recruiting
- Sponsor
- Roche
- Start
- Nov 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in autoimmune colitis comparing RO7790121 500 mg IV with Placebo IV (2 arms). Started Nov 2024; status: active, not recruiting.
02
Drugs
afimkibart
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on MOH_2024-11-26_013759.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-11-26_013759.